HTA157 Reflection on Medicines That Have Recently Come Off Patent and Have Been Rejected by NICE in the Past 20 Years: A Case Study of Abiraterone for Treating Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (MHSPC)
Abstract
Authors
O. Madani